Skip to main content

Versant Diagnostics Advances Dermatopathology with Acquisition of Cutaneous Pathology, P.A. Practice

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pathologist and dermatopathology luminary, Omar P. Sangueza, M.D., has joined Versant Diagnostics as they continue to expand their network of dermatopathologists across the country.

Grapevine, Texas, Aug. 20, 2024 (GLOBE NEWSWIRE) — Versant Diagnostics, an independent physician services company, today announced the acquisition of Cutaneous Pathology, P.A., a dermatopathology practice based in Winston-Salem, N.C. Internationally renowned pathologist and dermatopathology luminary, Omar P. Sangueza, M.D., has joined Versant Diagnostics as they continue to expand their network of dermatopathologists across the country.

Dr. Sangueza worked with the late A. Bernard Ackerman, M.D. while a Holtzman Fellow in Dermatopathology at New York University before going on to train many national and international dermatopathology fellows through various programs.  Dr. Sangueza has authored multiple publications and books on Dermatopathology and continues to be a highly sought after lecturer throughout the world. Among his many achievements and honors, Dr. Sangueza was granted the Award for Excellence in Teaching of Dermatopathology in 2014.

“We are honored to have Dr. Sangueza on our team,” says Dr. David Rowe, Regional Managing Director at Versant. “He is an incredible physician and trusted partner for the dermatopathology needs in our country and around the globe. His expertise will continue to make a positive impact on patient care by expanding access to our increasing network of specialists.”

Versant Diagnostics provides the necessary resources, infrastructure, and technology to their multi-specialty pathologists, with the mission to improve patient outcomes, elevate care, and save lives. Versant Diagnostics’ sub-specialty experts cover the areas of Dermatopathology, Gastrointestinal Pathology, Genitourinary Pathology, Hematopathology, Breast Pathology, Women’s Health/Gynecological Pathology, Renal Pathology, Clinical Pathology, and General Surgical Pathology.

“I could not be more excited to join the great people at Versant Diagnostics,” says Dr. Omar Sangueza. “The vision of the company, their commitment to excellence, and their devotion to providers and patients is truly remarkable and something I am pleased to be part of. Their values and goals align directly with mine.”

Versant Diagnostics is rapidly advancing the benefits of digital pathology in anatomic pathology labs and specialty clinics and has an aggressive growth strategy into additional markets and sub-specialties. For more information, visit www.versantdx.com and follow Versant Diagnostics on LinkedIn.

###

About Versant Diagnostics

Founded in 2021 by physician Ven Aduana, M.D. and operating executives Jim Billington and Brian Carr, Versant Diagnostics is focused on anatomic pathology and the digital transformation of the industry. By combining technological advancements in healthcare with a skilled set of subspecialty pathologists, Versant Diagnostics provides superior service for hospitals and physician practices. Learn more at www.versantdx.com.

CONTACT: Renee Cossman
renee@cossmanpr.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.